Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs RVL Pharmaceuticals PLC (RVLP)

Adaptimmune Therapeutics PLC and RVL Pharmaceuticals PLC are both Biotechnology companies. Adaptimmune Therapeutics PLC and RVL Pharmaceuticals PLC are of similar size ($14.6M and $14.1M). RVL Pharmaceuticals PLC grew revenue faster over the last twelve months: 5.64% against −54.0%. RVL Pharmaceuticals PLC has the higher net margin (−184.9% vs −262.5%) and the lower return on invested capital (−80.5% vs 0.00%). Across the 16 metrics below, Adaptimmune Therapeutics PLC leads on 8 and RVL Pharmaceuticals PLC on 8.

Valuation

Metric ADAPY RVLP Biotechnology median
P/E n/m n/m 8.50
P/S 0.12 n/m 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.12 1.05 9.21
Earnings yield (2,166.67%) 0.00% (33.15%)
Free cash flow yield (2,380.45%) 0.00% (25.50%)

Profitability

Metric ADAPY RVLP Biotechnology median
Gross margin 94.81% 74.73% 65.16%
Operating margin (427.75%) (191.72%) 0.00%
Net margin (262.46%) (184.91%) 0.00%
Free cash flow margin (288.20%) (128.42%) 0.00%
Return on equity (1,349.52%) (182.44%) (56.36%)
Return on assets 0.00% (64.94%) (48.04%)
Return on invested capital 0.00% (80.54%) 0.00%

Growth

Metric ADAPY RVLP Biotechnology median
Revenue growth (TTM) (53.99%) 5.64% 6.02%
EPS growth (last fiscal year) 142.86% 39.58% 30.26%
Revenue growth, 5-year CAGR 8.40% (27.35%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY RVLP Biotechnology median
Debt to equity (0.36) 3.54 0.00
Current ratio 1.52 0.38 4.72
Net debt to EBITDA 0.47 (0.29) 0.96

Dividend

Metric ADAPY RVLP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADAPY RVLP Biotechnology median
Market cap 14.55m 14.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack